OvaScience’s AUGMENT Treatment Shows Improved Pregnancy Rates And Live Births In Women With Poor Prognoses As Reported By Physicians During Annual International Fertility Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced that physicians continue to report improvements in pregnancy rates and live births with the AUGMENTSM treatment in women with very poor prognoses, including those with poor egg health and embryo quality. At a scientific symposium held during the European Society for Human Reproduction and Embryology (ESHRE) annual meeting, fertility experts discussed the importance of egg health for improving patient care and shared their patients’ experiences using the AUGMENT treatment during in vitro fertilization (IVF). The AUGMENT treatment is not available in the United States.

Help employers find you! Check out all the jobs and post your resume.